Median Effective Dose of Ciprofol-Assisted Sedation for Elderly Patients Undergoing Knee Arthroplasty

Sedation Clinical Trial

Official title:

Median Effective Dose of Ciprofol-Assisted Sedation for Elderly Patients Undergoing Knee Arthroplasty

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06293131
• Other study ID #: yuewei20230705
• Status: Completed
• Phase: Early Phase 1
• Start date: May 29, 2023
• Est. completion date: September 28, 2023

Study information

• Verified date: February 2024
• Source: Second Hospital of Shanxi Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Regional anesthesia is a common clinical anesthesia method, and regional anesthesia-assisted sedation play a central role in promoting patient comfort and relieving anxiety. With increasing age, elderly people experience changes in pharmacokinetics and pharmacodynamics and increased drug sensitivity. Ciprofol has advantages in adverse events such as hypotension and respiratory depression. There are fewer studies on the recommended dosage of ciprofol-assisted sedation for intrathecal anesthesia in elderly patients. The aim of study is to identify the median effective dose(ED50) of ciprofol-assisted sedation in elderly patients undergoing spinal anesthesia

Description:

Select the patients who received knee arthroplasty in the Second Hospital of Shanxi Medical University. The patients received a loading dosage of 0.05mg/kg of ciprofol to begin sedation following the completion of intravertebral anesthesia, and the maintenance dose is calculated using the sequential method. Based on the relevant literature and pilot study, 0.2 mg·kg-1·h-1 is selected as initial test dose with a dose gradient of 0.02 mg·kg-1·h-1. The Modified Alertness Sedation Score (MOAA/S ) scores and the bispectral index (BIS) were recorded for patients before administration (T0), 5 min after administration (T1), 10 min after administration (T2), 20 min after administration (T3), 30 min after administration (T4), 45 min after administration (T5), and 60min after administration (T6). If the first patient had ≥ 4 time points with MOAA/A score ≤3 and BIS<85 from T0-T6, the sedation was regarded as satisfactory, then the next patient 's dose of ciprofol was reduced by one level. On the contrary, if the patient's MOAA/S score and BIS at T0-T6 had less than 4 points of MOAA/S ≤3 points and BIS <85, it was regarded as unsatisfactory sedation. The next patient's dose of ciprofol was increased by one level. After 8 crossovers, the trial was terminated. At the same time, the change of vital signs and adverse reactions before and after administration were recorded

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: September 28, 2023
• Est. primary completion date: September 28, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Age = 65 years

• ASA grade I~III

• BMI 18~30 kg/m2

Exclusion Criteria:

• Contraindications to intrathecal anesthesia

• Suffering from severe psychiatric or neurologic disorders or taking sedative drugs within the last 3 months

• Difficult airway or having respiratory diseases such as upper airway obstruction

• Severe cardiovascular system diseases

• Severe hepatic or renal dysfunction

• Allergy or contraindication to propofol and its drug-related components

• Patient Prefusal

Related Conditions & MeSH terms

• ED50
• Knee Arthroplasty
• Sedation

Intervention

Drug:
• Ciprofol
Ciprofol was injected intravenously, and was pumped during operation to maintain sedation

Locations

Country	Name	City	State
China	Second Hospital of Shanxi Medical University	Taiyuan	Shanxi

Sponsors (1)

Lead Sponsor	Collaborator
Second Hospital of Shanxi Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Occurrence of Sedation-related adverse events	It includes intraoperative and postoperative sedation-related adverse events	72 hours
Primary	Modified Alertness Sedation Score (MOAA/S)	Changes in Modified Alertness Sedation Score	24 hours
Primary	Bispectral index (BIS)	Changes in Bispectral index	24 hours
Secondary	systolic blood pressure (SBP)	Changes in systolic blood pressure	24 hours
Secondary	diastolic blood pressure(DBP)	Changes in diastolic blood pressure	24 hours
Secondary	heart rate (HR)	changes in heart rate	24 hours
Secondary	pulse oxygen saturation(SpO2)	changes in pulse oxygen saturation	24 hours